Magne, J., Senechal, M., Dumesnil, J.G., Pibarot, P., Ischemic mitral regurgitation: a complex multifaceted disease. Cardiology 112 (2009), 244–259.
Vahanian, A., Alfieri, O., Andreotti, F., et al. Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 33 (2012), 2451–2496.
Nishimura, R.A., Otto, C.M., Bonow, R.O., et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 129 (2014), 2440–2492.
Chaput, M., Handschumacher, M.D., Tournoux, F., et al. Mitral leaflet adaptation to ventricular remodeling: occurrence and adequacy in patients with functional mitral regurgitation. Circulation 118 (2008), 845–852.
Chaput, M., Handschumacher, M.D., Guerrero, J.L., et al. Mitral leaflet adaptation to ventricular remodeling: prospective changes in a model of ischemic mitral regurgitation. Circulation 120:Suppl (2009), S99–S103.
Obase, K., Weinert, L., Hollatz, A., et al. Elongation of chordae tendineae as an adaptive process to reduce mitral regurgitation in functional mitral regurgitation. Eur Heart J Cardiovasc Imaging 17 (2016), 500–509.
Beaudoin, J., Handschumacher, M.D., Zeng, X., et al. Mitral valve enlargement in chronic aortic regurgitation as a compensatory mechanism to prevent functional mitral regurgitation in the dilated left ventricle. J Am Coll Cardiol 61 (2013), 1809–1816.
Dal-Bianco, J.P., Aikawa, E., Bischoff, J., et al. Myocardial infarction alters adaptation of the tethered mitral valve. J Am Coll Cardiol 67 (2016), 275–287.
Grande-Allen, K.J., Borowski, A.G., Troughton, R.W., et al. Apparently normal mitral valves in patients with heart failure demonstrate biochemical and structural derangements: an extracellular matrix and echocardiographic study. J Am Coll Cardiol 45 (2005), 54–61.
Walker, G.A., Masters, K.S., Shah, D.N., Anseth, K.S., Leinwand, L.A., Valvular myofibroblast activation by transforming growth factor-beta: implications for pathological extracellular matrix remodeling in heart valve disease. Circ Res 95 (2004), 253–260.
Wylie-Sears, J., Levine, R.A., Bischoff, J., Losartan inhibits endothelial-to-mesenchymal transformation in mitral valve endothelial cells by blocking transforming growth factor-β-induced phosphorylation of ERK. Biochem Biophys Res Commun 446 (2014), 870–875.
Bartko, P.E., Dal-Bianco, J.P., Guerrero, J.L., et al., for the Leducq Transatlantic Mitral Network. Effect of losartan on mitral valve changes after myocardial infarction. J Am Coll Cardiol 70 (2017), 1232–1244.
Acker, M.A., Parides, M.K., Perrault, L.P., et al. Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N Engl J Med 370 (2014), 23–32.
Goldstein, D., Moskowitz, A.J., Gelijns, A.C., et al. Two-year outcomes of surgical treatment of severe ischemic mitral regurgitation. N Engl J Med 374 (2016), 344–353.
Smith, P.K., Puskas, J.D., Ascheim, D.D., et al. Surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med 371 (2014), 2178–2188.
Michler, R.E., Smith, P.K., Parides, M.K., et al. Two-year outcomes of surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med 374 (2016), 1932–1941.
Dickstein, K., Kjekshus, OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on morbidity and mortality in high risk patients after acute myocardial infarction. Lancet 360 (2000), 752–760.
Rossebo, A.B., Pedersen, T.R., Boman, K., et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 359 (2008), 1343–1356.
